Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes

被引:15
作者
Bruha, Radan
Vitek, Libor
Petrtyl, Jaromir
Lenicek, Martin
Urbanek, Petr
Zelenka, Jaroslav
Jachymova, Marie
Svestka, Tomislav
Kalab, Milan
Dousa, Miroslav
Marecek, Zdenek
机构
[1] Charles Univ, Fac Med 1, Dept Med 4, CZ-12808 Prague 2, Czech Republic
[2] Charles Univ, Inst Clin Biochem & Lab Diagnost, Gen Teaching Hosp, Fac Med 1, Prague, Czech Republic
[3] Cent Mil Hosp, Prague, Czech Republic
关键词
beta-blockers; carvedilol; endothelial dysfunction; inflammatory cytokines; portal hypertension; treatment;
D O I
10.1080/00365520600780403
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. Bleeding from esophageal varices is a major complication of liver cirrhosis. Non-selective beta-blockers exert an influence on the functional part of portal hypertension, thereby reducing the risk of bleeding. Direct measurement of this functional part is not possible; nevertheless, pro-inflammatory markers as well as parameters of endothelial dysfunction might serve as surrogate markers. The aim of study was to assess the correlation between the therapeutic efficacy of carvedilol and markers of endothelial dysfunction and systemic inflammation in patients with liver cirrhosis and portal hypertension. Material and methods. Thirty-six patients with cirrhosis and portal hypertension were given carvedilol, 25 mg q.i.d. for 30 days. Hepatic venous pressure gradient (HVPG) and biochemical determinations were performed prior to and after the treatment. Eight healthy individuals served as controls for comparison of biochemical markers. Results. In the whole group of cirrhotic patients, HVPG decreased from 17.7 +/- 3.8 to 14.9 +/- 4.8 mmHg (p < 0.001). Complete response was seen in 15 patients (42%). Baseline serum levels of E-selectin were significantly higher in responders than in non-responders (119.89 +/- 70.6 versus 52.69 +/- 25.7 ng/ml; p = 0.023) and in controls (28.89 +/- 22.2 ng/ml; p = 0.004). Furthermore, baseline TNF-alpha a levels were significantly higher in responders than in non-responders (22.8 +/- 15.7 versus 7 +/- 8.9; p = 0.047) and in controls (5.5 +/- 5.9 pg/ml; p = 0.005). Serum levels of ICAM-1 showed the same trend (4360 +/- 2870 versus 2861 +/- 1577 versus 651 +/- 196 ng/ml), although differences did not reach statistical significance. Conclusions. Markers of systemic inflammation and endothelial dysfunction seem to predict the hypotensive effect of carvedilol on portal hypertension in patients with liver cirrhosis and may be useful in the assessment of the efficacy of the therapy.
引用
收藏
页码:1454 / 1463
页数:10
相关论文
共 46 条
[11]   A la carte treatment of portal hypertension:: Adapting medical therapy to hemodynamic response for the prevention of bleeding [J].
Bureau, C ;
Péron, JM ;
Alric, L ;
Morales, J ;
Sanchez, J ;
Barange, K ;
Payen, JL ;
Vinel, JP .
HEPATOLOGY, 2002, 36 (06) :1361-1366
[12]  
CAHILL PA, 2001, PHARMACOL THERAPEUT, V89, P293
[13]  
CARLOS TM, 1994, BLOOD, V84, P2061
[14]  
DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145
[15]   Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics [J].
De, BK ;
Das, D ;
Sen, S ;
Biswas, PK ;
Mandal, SK ;
Majumdar, D ;
Maity, AK .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (02) :183-189
[16]  
De Franchis R, 2001, P 3 BAV INT CONS WOR
[17]   Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension [J].
Debernardi-Venon, W ;
Barletti, C ;
Alessandria, C ;
Marzano, A ;
Baronio, M ;
Todros, L ;
Saracco, G ;
Repici, A ;
Rizzetto, M .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (02) :401-404
[18]  
DUPOONT AG, 1987, J CARDIOVASC PHARM S, V11, P130
[19]   RELATION BETWEEN PORTAL PRESSURE RESPONSE TO PHARMACOTHERAPY AND RISK OF RECURRENT VARICEAL HEMORRHAGE IN PATIENTS WITH CIRRHOSIS [J].
FEU, F ;
GARCIAPAGAN, JC ;
BOSCH, J ;
LUCA, A ;
TERES, J ;
ESCORSELL, A ;
RODES, J .
LANCET, 1995, 346 (8982) :1056-1059
[20]   Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis [J].
Forrest, EH ;
Bouchier, IAD ;
Hayes, PC .
JOURNAL OF HEPATOLOGY, 1996, 25 (06) :909-915